Headquartered in Virginia, ADial Pharmaceutical is focused on developing medicines to treat alcoholism, substance abuse, and addictive behaviors. With estimated costs of alcohol treatment and prevention at $7.5 billion annually, and only 1% spent on prescription medications, there is a sizeable opportunity for a 4-5 year investment in ADial Pharmaceuticals that should realize a significant return.

With secure patents, a highly qualified management team, unique medicines under development, and a clearly defined market opportunity, ADial is seeking $3 million in initial funding to establish an infrastructure and prepare for the phase III clinical trial of a proprietary medication currently in development for alcohol dependence and abuse.

Parties interested in investment opportunities should contact:

Michael Torok, PhD
1926 Abbey Rd., Suite #4
Charlottesville, VA 22911
(434) 249-2544
email: mtorok@adialpharma.com